QT Imaging Holdings, Inc.

Good day and welcome to the QT Imaging Holdings first quarter 2026 financial results conference call. All participants will be in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch tone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Bruce Voss. Please go ahead.

This is Bruce Voss with Alliance Advisors IR. Thank you for participating in today's call. Joining me from QT Imaging Holdings are Dr. Raluca Dinu, Chief Executive Officer, and Jay Jennings, Chief Financial Officer. I would like to remind listeners that comments made during this call by management will include forward-looking statements within the meaning of federal securities laws. Any statements that are not statements of historical facts should be deemed to be forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. All forward-looking statements are based on QT imaging's current beliefs as well as assumptions made by and information currently available to QT imaging and relate to, among other things, QT imaging's breast acoustic CT scanner, including its product commercialization and manufacturing, the evolution of QT imaging into a scalable imaging platform, the QTI cloud platform and SAS model, performance of software enhancements, new product development and introduction, and product sales growth and projected revenues. For a list and description of the risks and uncertainties associated with the company's business, please see its filings with the Securities and Exchange Commission. Furthermore, the content of this call contains information that is accurate only as of the date of the live broadcast, May 13, 2026. QT imaging disclaims any obligation, except as required by law, to update or revise any financial or operational projections or other forward-looking statements, whether because of new information, future events, or otherwise. And now I'd like to turn the call over to Dr. Raluca Dinu. Raluca?

Thank you, Bruce, and good afternoon, everyone. Thank you for spending the time with us and for your interest in QT imaging. The first quarter of 2026 was a highly productive period for QT imaging as it continues to execute across commercialization, clinical validation, reimbursement, regulatory expansion, and software innovation. We believe that the progress achieved during the quarter further strengthens the foundation for the long-term adoption of our technology and supports our strategy of building a leading quantitative breast imaging platform. During the quarter, we shipped 13 QT Breast Acoustic CT systems, which was in line with our commercial distribution commitments. These shipments reflect continued operational execution and growing commercial activity as we expand our installed base, both domestically and internationally. We're also pleased to announce that subsequent to the close of the quarter, the maturity date of our Senior Secure Term Loan with Linn-Rock Lake was extended by two years, from March 31st, 2027 to March 31st, 2029. We would like to thank Linn-Rock Lake for their continued support and confidence in QT imaging. This extension provides the company with additional financial flexibility as we continue executing on our commercial, clinical, and strategic growth initiatives. On the reimbursement front, We achieved an important milestone with the approval by the American Medical Association of a new Category 3 CPT code for our technology, effective January 1, 2027. We believe this is a meaningful step toward broader clinical adoption, standardized reporting, utilization tracking, and future reimbursement pathways for our technology. We also received FDA 510K clearance for enhancement to our breast acoustic CT scanner and platform designed to improve visualization and imaging coverage of posterior breast tissue. This region has historically been challenging to evaluate with traditional breast imaging technologies, and we believe the updated configuration further improves the clinical utility and overall performance of our systems. On the international regulatory front, we secured official classification and clearance in the United Arab Emirates for both our QT breast acoustic CT scanner and the QTI SAS cloud platform under our distribution agreement with Al-Naghi Medical Company. We also continue to advance our software ecosystem and imaging capabilities. During the quarter, we launched the QT Imaging Golea Viewer, an innovative multi-modality imaging platform designed to support efficient review and correlation of imaging findings across modalities while enabling longitudinal patient evaluation and quantitative analysis. In parallel, we released software version 4.5.0, a next-generation image reconstruction update that improves spatial resolution in reflection imaging and enhances image quality while maintaining efficient processing times. We believe continuous software innovation will remain a key differentiator and advantage for QT imaging as we expand our install base and advance toward a more scalable imaging and data platform. Importantly, our commercial efforts continue to be supported by growing clinical evidence generated at leading institutions. For example, at the Mayo Clinic, a prospective feasibility study evaluating QT scan as a supplemental screening tool compared to an MRI in high-risk women provided encouraging early validation of the technology. The study demonstrated absolute agreement between QT imaging and MRI, suggesting comparable effectiveness of QT imaging and MRI in identifying positive findings. We also continue to strengthen our clinical and medical advisory team. During the quarter, we welcome Dr. Maryam Ashita as senior clinical advisor to support our clinical strategy, reader training activities, and development of structured interpretation pathways for QT scan. More recently, we welcome Dr. Barry Rosman, a senior medical advisor. Dr. Rosman is a breast surgical oncologist with more than 25 years of experience treating breast cancer and breast disease. He currently operates Advanced Breast Care Surgical Oncology of North Georgia, which is a comprehensive breast imaging and diagnostic center. His engagement with QT imaging includes implementation of QT scan within his busy clinical practice, to support physician training, workflow integration, patient access, and the collection of real-world clinical and operational experience with the technology. Given his extensive experience treating women with dense breast tissue, Dr. Rosemond understands firsthand the limitation of existing imaging modalities, which can miss cancers in dense breasts, and the need for additional technologies capable of providing more quantitative and clinically meaningful information. We believe QT imaging technology is uniquely positioned as a radiation-free, compression-free, true 3D breast imaging platform capable of delivering quantitative information that may improve clinical decision-making, particularly for women with dense breasts. More broadly, we believe QT imaging sits at the intersection of advanced imaging, quantitative diagnostics, and AI-enabled healthcare infrastructure. Overall, we remain focused on discipline execution as we continue expanding commercialization efforts, advancing our technology platform, and building long-term value for patients, providers, and shareholders. Now I'll turn the call over to our CFO, Jay Jennings, to review our financial results. Jay?